AgingResearch.NewsJoin free

MBX Biosciences

CompanyUnited States

MBX Biosciences develops one asset, in phase 1 (MBX 4291 in obesity). Mostly peptide; based in the United States.

1
Asset
Furthest stage
Phase 1
Raised
$504M
1
Trial
1
Signal

Pipeline

1

  • MBX 4291

    GLP-1 and GIP receptor co-agonist

    Phase 1, Peptide, obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Funding rounds and grants8
  • People1
  • Signals1
  • Similar companies6

Papers

Intelligence